Select patients for treatment with Capmatinib based on the presence of a mutation that leads to MET exon 14 skipping in tumor or plasma specimens. If a mutation that leads to MET exon 14 skipping is not detected in a plasma specimen, test tumor tissue if feasible.
The recommended dosage of Capmatinib is 400 mg orally twice daily with or without food. Swallow Capmatinib tablets whole. Do not break, crush or chew the tablets. If a patient misses or vomits a dose, instruct the patient not to make up the dose, but to take the next dose at its scheduled time.
The recommended dose reductions for the management of adverse reactions are listed in Table 1.
Permanently discontinue Capmatinib in patients who are unable to tolerate 200 mg orally twice daily.
The recommended dosage modifications of Capmatinib for adverse reactions are provided in Table 2.
from FDA,2023.03
Capmatinib can be used to treat patients with METex14-mutated non-small cell lun···【more】
Release date:2024-08-07Recommended:119
Capmatinib is an oral MET inhibitor that received Breakthrough Therapy Designati···【more】
Release date:2024-08-07Recommended:135
Capmatinib is a targeted drug used to treat a specific type of non-small cell lu···【more】
Release date:2024-08-07Recommended:153